---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-24-000009"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:07:17.302441+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics reports Q4 2023 net loss of $19.4M, ends year with $131.4M cash

## Summary
- Net loss Q4 2023 $19.4M vs $21.1M in Q4 2022; full year net loss $82.4M vs $91.2M.
- Cash, cash equivalents, investments $131.4M at Dec 31, 2023; expected to fund operations into Q2 2025.
- Dosed first patient in Phase 2 trial of BDTX-1535 in 1L non-classical EGFRm NSCLC; Phase 2 data expected Q3 2024.
- GBM results for BDTX-1535 in Q2 2024, initial results for BDTX-4933 in KRASm NSCLC in Q4 2024.
- R&D expenses decreased to $59.4M for FY2023 from $64.4M in FY2022, primarily due to reduced early discovery spend.

## SEC filing metadata
- accession: 0001701541-24-000009
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000009/0001701541-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000009/bdtx-20240312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-24-000009
- JSON: https://secwatch.observer/filing/0001701541-24-000009.json
- Plain text: https://secwatch.observer/filing/0001701541-24-000009.txt

## Key facts
- Earnings Releases
  Black Diamond Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $82.4 million.
  - Period: the year ended December 31, 2023
  - Net income: Net loss for the year ended December 31, 2023 was $82.4 million
  - Result: reported results
  source text: Net loss for the year ended December 31, 2023 was $82.4 million compared to $91.2 million for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000009/0001701541-24-000009-index.htm
- Earnings Releases
  Black Diamond Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $19.4 million.
  - Period: the fourth quarter ended December 31, 2023
  - Net income: Net loss for the fourth quarter of 2023 was $19.4 million
  - Result: reported results
  source text: Net loss for the fourth quarter of 2023 was $19.4 million, as compared to $21.1 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000009/0001701541-24-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.